Palisade Total Current Liabilities from 2010 to 2024

PALI Stock  USD 2.46  0.04  1.65%   
Palisade Bio's Total Current Liabilities is increasing with very volatile movements from year to year. Total Current Liabilities is estimated to finish at about 3.4 M this year. Total Current Liabilities is the total amount of liabilities that Palisade Bio is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2006-06-30
Previous Quarter
2.8 M
Current Value
2.7 M
Quarterly Volatility
2.1 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Palisade Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Palisade Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 K, Interest Expense of 14.2 K or Selling General Administrative of 6.6 M, as well as many indicators such as Price To Sales Ratio of 17.64, Dividend Yield of 0.0 or PTB Ratio of 0.34. Palisade financial statements analysis is a perfect complement when working with Palisade Bio Valuation or Volatility modules.
  
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.

Latest Palisade Bio's Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Palisade Bio over the last few years. Total Current Liabilities is an item on Palisade Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Palisade Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Palisade Bio's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Palisade Bio's overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Very volatile
   Total Current Liabilities   
       Timeline  

Palisade Total Current Liabilities Regression Statistics

Arithmetic Mean3,443,742
Geometric Mean2,611,411
Coefficient Of Variation70.36
Mean Deviation1,954,210
Median2,586,000
Standard Deviation2,423,086
Sample Variance5.9T
Range7.7M
R-Value0.06
Mean Square Error6.3T
R-Squared0
Significance0.82
Slope34,971
Total Sum of Squares82.2T

Palisade Total Current Liabilities History

20243.4 M
20232.6 M
2022M
20212.5 M
20208.1 M
20191.2 M
20181.1 M

About Palisade Bio Financial Statements

Investors use fundamental indicators, such as Palisade Bio's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Palisade Bio's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Current Liabilities2.6 M3.4 M

Currently Active Assets on Macroaxis

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.26)
Return On Assets
(0.59)
Return On Equity
(1.10)
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.